Aktifitas Antibiotik Ceftazidime-Avibactam Dan Ceftaroline Secara In Vitro Terhadap Isolat Klinis Di Pekanbaru

Chandra Wijaya


Ceftaroline and Ceftazidime–avibactam are relatively new antibiotics that show good effectiveness against antibiotic-resistant pathogens. Both of these antibiotics are now available worldwide, but reports of resistance to them are also starting to emerge. This study aimed to evaluate the in vitro activity of the antibiotic Ceftazidime-avibactam combination of 100 clinical isolates consisting of Enterobacteriaceae and Pseudomonas aeruginosa bacteria and to evaluate the antibiotic effect of Ceftaroline against 100 clinical isolates of Enterobacteriaceae and Staphylococcus sp. This study is observational with cross-sectional study design. The study was conducted at the microbiology laboratory of a private hospital at Pekanbaru Riau in Januari-June 2021. There were 100 clinical isolates tested with Ceftaroline and Ceftazidime-avibactam. The sensitivity to Ceftaroline and Ceftazidime-avibactam were reported as a number isolate and percentage. The results showed the sensitivity of bacteria K. pneumoniae, E. coli, Enterobacter sp, and P. aeruginosa, to Ceftazidime-Avibactam were 87%, 90%, 66%, and 82%, respectively. The sensitivity of the antibiotic Ceftaroline to the bacteria K. pneumoniae, E. coli, Enterobacter sp and Staphylococcus sp. were 39%, 54%, 36.4%, 67% and 75%, respectively. Based on these results, the antibiotic ceftazidime avibactam can be used for the treatment of suitable pathogenic infections because of its fairly good sensitivity (>80%) to Enterobacteriaceae and P. aeruginosa bacteria. Ceftaroline antibiotics are not recommended to be used as a therapeutic option, because of the high resistance to Enterobacteriaceae and Staphylococcus sp. Further research is needed to determine the molecular mechanism of resistance to Ceftaroline antibiotics


Ceftazidime-avibactam, Ceftaroline, antibiotic resistance, culture sensitivity test

Full Text:



Dancer SJ. The problem with cephalosporins. Journal of Antimicrobial Chemotherapy.2001; 48: 463–478

Caprile KA. The cephalosporin antimicrobial agents: a comprehensive review. J Vet Pharmacol Ther.1988;11:1–32

Karlowsky JA, Adam HJ, Baxter MR. In vitro activity of ceftaroline-avibactam against Gram-negative and Gram-positive pathogens isolated from patients in Canadian hospitals in 2010–2012: results from the CANWARD Surveillance Study. Antimicrob Agents Chemother. 2013; 57:5600–5611

Zhanel GG, Lawson CD, Adam H. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73: 159–177

Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014 Jan 24; 9: 13-25. doi: 10.2147/CE.S40698. PMID: 24493994; PMCID: PMC3908787.

Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children, Clinical Infectious Diseases, 2011; 52(3): e18–e55, https://doi.org/10.1093/cid/ciq146

Halim SV, Setiawan, E. Seftarolin, Antibiotik baru dengan aktivitas Anti-MRSA: sebuah kajian efektivitas, keamanan, dan biaya penggunaan. Jurnal Farmasi Galenika. 2020; 6(1):160-180. doi:10.22487/j24428744.2020.v6.i1.15015

Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus. Reviews of anti-infective agents. Clinical Infectious Diseases 2011; 52(9):1156–1163

O'Neill J Tackling a crisis for the health and wealth of nations – AMR. The Review on Antimicrobial Resistance. The Review. The Lancet Infectious Diseases. 2014; 14(8): 742–750. Available at https://amr-review.org › sites › default › files

Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. Journal of Antimicrobial Chemotherapy. 2014; 69 (8): 2065–2075

Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime–avibactam and underlying mechanisms. / Journal of Global Antimicrobial Resistance.2020; 22: 18–27

Mark Laws M, Shaaban A, Rahman KM. Antibiotic resistance breakers: current approaches and future directions. FEMS Microbiology Reviews. 2019; 43; 490–516

Sievert DM. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. ICHE 2013; 34:1–14

Smyth DS, McDougal LK, Gran FW, Manoharan A, Enright MC, Song JH, et al Population structure of a hybrid clonal group of methicillin-resistant Staphylococcus aureus, ST239-MRSA-III. PLoS One5: e8582. 10.1371/journal.pone.0008582.

Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, Chantratita N, Gardete S, Tavares A, Day N, Lindsay JA, Edgeworth JD, de Lencastre H, Parkhill J, Peacock SJ, Bentley SD. Evolution of MRSA during hospital transmission and intercontinental spread. Science. 2010; 327:469–474. 10.1126/science.1182395.

Long, W, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez Ket al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrobial Agents and Chemotherapy. November 2014; 58(11): p. 6668 – 6674

WHO. Acces, Watch, Reserve (AWaRe) classification of antibitiotics for evaluation and monitoring use, 2021.Geneva: World Health Organization (who/hmp/hps/eml/2021.04). Licence: CC-BY-NC-SA3.0 IGO.

Hadi U. Antibiotic usage and antimicrobial resistance in Indonesia. Tropical Medicine and International Health; 2008;13(7): 888-99

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. 31st ed. Clinical and Laboratory Standards Institute. 2021.

Budayanti NS, Aisyah DN, Fatmawati NND, Tarini NMA, Kozlakidis Z, Adisasmito W. Identification and distribution of pathogens in a major tertiary hospital of Indonesia brief research report article. Front. Public Health, 31 January 2020 | https://doi.org/10.3389/fpubh.2019.00395

Estiningsih D, Puspitasari I, Nuryastuti T. Identifikasi infeksi multidrug-resistant organisms (MDRO) pada pasien yang dirawat di bangsal Neonatal Intensive Care Unit (NICU) RSUP Dr.Soeradji Tirtonegoro Klaten. Jurnal Manajemen dan Pelayanan Farmasi. 2016; 6 (3).

Radji M, Fauziah S, Aribinuko N. Antibiotic sensitivity pattern of bacterial pathogens in the intensive care unit of Fatmawati Hospital, Indonesia. Asian Pacif J Trop Biomed. 2011; 1:39–42. doi: 10.1016/S2221-1691(11)60065-8

Novard MFA, Suharti N, Rasyid R. Gambaran bakteri penyebab infeksi pada anak berdasarkan jenis spesimen dan pola resistensinya di Laboratorium RSUP Dr. M. Djamil Padang Tahun 2014-2016. Jurnal Kesehatan Andalas. 2019; 8 (Supplement 2).

Patwardhan R, Dhakephalkar P, Niphadkar K, Chopade B. A study on nosocomial pathogens in ICU with special reference to multiresistant Acinetobacter baumannii harbouring multiple plasmids. Ind J Med Res. 2008; 128:178.

Wong SY, Manikam R, Muniandy S. Prevalence and antibiotic susceptibility of bacteria from acute and chronic wounds in Malaysian subjects. J Infect Dev Countr. 2015; 9:936–44. doi: 10.3855/jidc.5882

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. https://doi. org/10.1111/j.1469-0691.2011.03570.x

Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century:a clinical super-challenge. N Engl J Med. 2009;360(5):439–43. https://doi.org/10.1056/ NEJM p0804651.

Qureshi S, Maria N, Zeeshan M, Irfan S, Qamar FN. Prevalence and risk factors associated with multi-drug resistant organisms (MDRO) carriage among pediatric patients at the time of admission in a tertiary care hospital of a developing country. BMC Infectious Diseases. 2021; 21:547 https://doi.org/10.1186/s12879-021-06275-5

Roth B, Laps A, Stafford K, Heil E, Hachaambwa L, Yamba K, et al. High-frequency of multi-drug-resistant organisms (MDRO) at University Teaching Hospital (UTH), Lusaka, Zambia Poster Abstracts. OFID 2018:5 (Suppl 1): S169

Nichols WW, Newell P, Critchley IA, Riccobene T, Das S. Avibactam pharmacokinetic/pharmacodynamic targets. Antimicrob Agents Chemother. 2018; 62: e02446-17. https://doi.org/10.1128/AAC.02446-17

Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. Emergence of Ceftazidime-Avibactam resistance due to Plasmid-Borne blaKPC-3 Mutations during treatment of Carbapenem-Resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02097-16. doi: 10.1128/AAC.02097-16. PMID: 28031201; PMCID: PMC5328542.

Karlowsky JA, Adam HJ, Baxter MR. In vitro activity of ceftaroline-avibactam against Gram-negative and Gram-positive pathogens isolated from patients in Canadian hospitals in 2010–2012: results from the CANWARD Surveillance Study. Antimicrob Agents Chemother. 2013;57:5600–5611

Sader, HS. Antimicrobial Activity of Ceftazidime-Avibactam Tested against MultidrugResistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016. Antimicrob Agents Chemother 2017;61(11):e01045.

Zhang H, Xu Y, Jia P, Zhu Y, Zhang G, Zhang J, Duan S et al. Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016). Antimicrob Resist Infect Control. 2020; 9:166

Ślusarczyk R, Bielejewska A, Bociek A, Bociek M. Resistance to ceftaroline - 2018 review. European Journal of Biological Research 2018; 8 (3): 112-120

Rosanova MT, Aguilar PS, Sberna N, Led R. Efficacy and safety of ceftaroline: systematic review and meta-analysis. Ther Adv Infectious Dis 1–13. 2018.

Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus. reviews of anti-infective agents. Clinical Infectious Diseases. 2011;52(9):1156–1163

Gaikwad V, Gohel T, Panickar S, Chincholkar V, Mangalkar S. In vitro activity of ceftaroline: a novel antibiotic against methicillin-resistant Staphylococcus aureus. Indian J Pathol Microbiol. 2016; 59: 496.

Andrey DO, François P, Manzano C, Bonetti EJ, Harbarth S, Schrenzel J, et al. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013- 2014 at the Geneva University Hospitals. Eur J Clin Microbiol Infect Dis. 2017; 36: 343-350.

Iaconis JP, Reiszner E, Sahm DF. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. J Antimicrob Chemother. 2016; 71: 162-169

Athans V, Neuner EA, Hassouna H, Richter SS, Keller G, Castanheira M, Brizendine KD, Mathers AJ. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01551-18. doi: 10.1128/AAC.01551-18. PMID: 30578403; PMCID: PMC6325210


  • There are currently no refbacks.